Your Location:Home > News > Our News
Takeda China joins hands with Baheal Medical to continue strategic cooperation in the field of digestion
Release Time:2022-08-16 View Count:426

On August 16, 2022, Qingdao Baheal Medical INC. (hereinafter referred to as “Baheal Medical”, 301015.SZ) announced the signing of a renewal agreement with Takeda (China) Investment Co., Ltd. (hereinafter referred to as “Takeda China”) in Qingdao, China. Relying on Baheal Medical’s professional online and offline market commercialization capabilities, the two sides will work together to continue to deepen the promotion of Takeda China's products including Takepron (lansoprazole enteric- coated capsules), Pantoloc (pantoprazole sodium enteric coated tablets), Provacid (lansoprazole orally disintegrating tablets) to better benefit Chinese patients with digestive diseases.


guanwangpeitu.jpg


Mr. Shan Guohong, global senior vice president of Takeda pharmaceutical, President of Takeda China, and Mr. Zhao Xianzhou, head of business and multi-channel promotion of Takeda China, Mr. Fu Gang, chairman of Baheal Medical, Ms. Zhang Yuan, vice president of Baheal Medical and Mr. Wang Tingwei, vice president of Baheal Medical, attended and witnessed the signing ceremony.

As early as 2017, Takeda China reached retail channel commercialization cooperation with Baheal Medical for many of its digestive drug brands. Takeda China was also the first multinational pharmaceutical company to sign a contract with Baheal Medical ' health brand commercialization platform. During the cooperation period, with its professional brand commercialization capabilities, Baheal Medical has successfully promoted the rapid release of values of Takeda series products in retail channels, and the sales performance has grown steadily, helping Chinese patients to benefit widely.

Regarding the renewal of the contract, Mr. Shan Guohong, global senior vice president of Takeda pharmaceutical and President of Takeda China, said: "as a global biopharmaceutical enterprise driven by R & D, Takeda always adheres to the concept of 'patient first' and uses global innovation achievements to meet the unmet medical needs of domestic patients. At the same time, we are also actively working with domestic partners to explore innovative models to help more patients benefit from industry-leading treatment schemes. Takeda China and Baheal Medical have a good foundation for cooperation in the past. We highly recognize Baheal Medical's excellent brand commercialization capabilities, which helped Takeda China's brand products to cover many patients in the past cooperation. This renewal is to continue to promote the deeper coverage of high-quality brand products of Takeda China and benefit more Chinese patients in a more efficient and convenient way by virtue of the third-party commercialization platform of Baheal Medical. In the future, the two sides will fully integrate resources and explore ways of cooperation in more fields.”

Mr. Fu Gang, chairman of Baheal Medical, said: "The cooperation between Takeda China and Baheal Medical is of landmark significance. The two sides took the lead in exploring an innovative commercial cooperation mode. Based on a highly consistent enterprise value concept and a good cooperation foundation, Baheal Medical will continue to provide commercial escort services for Takeda China’s series products by virtue of its professional capabilities in brand operation and digital marketing, help the products release their value, and work together to provide disease treatment solutions for patients."

This renewal marks a new chapter of long-term cooperation between Takeda China and Baheal Medical. In the future, the two sides will further display their respective advantages, constantly expand diversified cooperation opportunities, and create a practical model for industrial win-win cooperation.

Share:
Back to Top